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Abstract
Background: Primary central nervous system lymphoma (PCNSL) is a frequent complication in
acquired immunodeficiency syndrome (AIDS). The objective of this survey was to investigate
incidence, clinical features, radiological findings, histologic diagnosis, treatment and outcome for all
patients with histologically verified AIDS-related PCNSL diagnosed in Norway in 1989–2003.
Methods: We identified the patients by chart review of all cases recorded as PCNSL in The
Norwegian Cancer Registry (by law recording all cases of cancer in Norway) and all cases recorded
as AIDS-related PCNSL in the autopsy registry at a hospital having 67% autopsy rate and treating
59% of AIDS patients in Norway, from 1989 to 2003. Histologic material and radiological images
were reviewed. We used person-time techniques to calculate incidence rates of PCNSL among
AIDS patients based on recordings on AIDS at the Norwegian Surveillance System for
Communicable Diseases (by law recording all cases of AIDS in Norway).
Results: Twenty-nine patients had histologically confirmed, newly diagnosed AIDS-related PCNSL
in Norway from 1989–2003. Only 2 patients had this diagnosis established while alive. AIDS
patients had 5.5% lifetime risk of PCNSL. Their absolute incidence rate of PCNSL per 100 person-
years was 1.7 (95%CI: 1.1–2.4) and decreased during the consecutive 5-year periods from 3.6, to
2.5, and to 0.4 (p < 0.001). Median survival from initial symptom of PCNSL was 2.3 months, but
one patient was still alive 4 years after completed radiotherapy.
Conclusion: This is the first national survey to confirm decreasing incidence of AIDS-related
PCNSL. Despite dismal survival in most patients, the possibility of long term survival should prompt
more aggressive diagnostics in suspected PCNSL.
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Primary central nervous system lymphoma (PCNSL) has
been diagnosed in at least 2% of individuals infected with
human immunodeficiency virus (HIV) [1], and in 9–14%
of acquired immunodeficiency syndrome (AIDS)-autop-
sies [2-4]. PCNSL is, after toxoplasmosis, the most com-
mon cause of focal brain lesions in AIDS patients [1,5].
The reported median survival in AIDS-related PCNSL is
1.0–2.5 months with supportive care only [6,7] and 2.0–
5.5 months with whole brain radiation therapy [1,8]. The
incidence of PCNSL among AIDS patients has been
reported to decline in the era of highly active antiretroviral
therapy (HAART), introduced in 1996 [8-14].
Few studies on AIDS related PCNSL were population
based [3,9,15-17]. This survey is, to the best of our knowl-
edge, the first comprising a whole country. Its objective
was to investigate incidence, clinical features, radiological
findings, histologic diagnosis, treatment and outcome for
all patients with histologically verified AIDS-related
PCNSL diagnosed in Norway in 1989–2003.
Methods
This study complied with the Helsinki Declaration. The
Regional Committee for Medical Research Ethics, the
Directorate for Health and Social Affairs and The Data
Inspectorate approved the study and waived informed
consent.
Norway (population of 4.2 million in 1989 and 4.6 mil-
lion in 2003) has mandatory cancer reporting to the Nor-
wegian Cancer Registry. This national registry recorded
180 patients with PCNSL diagnosed from 1 January 1989
to 31 December 2003. Medical records of all patients were
reviewed. Histologically verified AIDS-related PCNSL was
found in 23 of the 180 patients (98 had non-AIDS PCNSL
and 59 no PCNSL) [18]. During the studied 15-year
period Ullevaal University Hospital treated 59% (423/
723) of reported new cases of AIDS in Norway and autop-
sied 67% (186/278) of their AIDS deaths. A search in their
AIDS autopsy registry identified 6 additional cases of
AIDS-related PCNSL.
This study sample thus consisted of 29 AIDS patients with
histologically verified PCNSL; 27 were diagnosed and
treated at Ullevaal University Hospital. Clinical features,
histologic diagnosis, radiological findings, treatment and
outcome were registered. HAART was defined as the
administration of three or more antiretroviral agents
including a protease inhibitor or non-nucleoside reverse
transcriptase inhibitor. One pathologist (AKG) re-exam-
ined histologic material of all these patients from biopsy
(n = 2) or autopsy (n = 27) and reclassified it according to
the current WHO-classification (2001). For immunohis-
tochemistry, the antibodies CD3, CD20 and Ki67 were
used as a minimum. Epstein-Barr virus hybridization was
performed in 25 patients. Twenty-six patients had a com-
plete autopsy of the entire body (excluding systemic lym-
phoma). The remaining 3 patients underwent biopsy (n =
2) or autopsy (n = 1) of the brain only; none of them had
signs of lymphoma at chest- and abdomen imaging (n =
3) or bone marrow biopsy (n = 2). Cause of death was
established from medical records, autopsy reports and
death certificates.
In 14 included patients (1 of 12 diagnosed in 1989–1993,
13 of 17 diagnosed in 1994–2003) images from com-
puted tomography (CT) (in 14) and magnetic resonance
imaging (MRI) (in 4) prior to histologic diagnosis were
available for review. (In Norway hospitals are not obliged
to store radiological images for more than 10 years.) A
neuroradiologist (JK) and a general radiologist (ISH)
reviewed the images, first individually and then together.
Results are based on consensus from the joint review.
Number of new cases with AIDS and number of AIDS
deaths in Norway each year were obtained from MSIS
(The Norwegian Surveillance System for Communicable
Diseases). Named AIDS reporting from laboratories and
clinicians to this national surveillance system has been
mandatory in Norway since 1983 [19].
Statistical analyses
We calculated absolute incidence rates of PCNSL among
persons with AIDS based on numbers of newly diagnosed
AIDS-related PCNSL and numbers of patients living with
AIDS the same year (PYAR; Person-Years-At-Risk) (data
from MSIS). Trend test and 95% confidence interval (CI)
for incidence was calculated according to the Poisson dis-
tribution.
Duration of survival was calculated as time between date
of first symptom attributable to PCNSL and date of death
or January 1st 2008. Survival curves were calculated and
plotted using the method of Kaplan and Meier. All p-val-
ues in the analyses are two-sided. The analyses were per-
formed with Stata 9.0 (College Station, TX) and SPSS 14.0
(Chicago, IL).
Results
In Norway the absolute incidence rate of PCNSL among
AIDS patients per 100 person-years in 1989–2003 was 1.7
(95%CI: 1.1–2.4) and decreased from 3.6, to 2.5, and to
0.4 the consecutive 5-year periods (p < 0.001) (Figure 1).
The average annual incidence rate of AIDS-related PCNSL
among inhabitants in Norway was 0.44 per million
(95%CI: 0.30–0.64). The proportion of AIDS-deaths diag-
nosed with concomitant PCNSL was 5.5% (28/508). This
proportion was stable over time (5.3% (12/227), 6.0%
(13/215) and 4.6% (3/66) in 1989–1993, 1994–1998Page 2 of 8
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AIDS-related PCNSL in Norway: new cases, incidence rates and Person-Years-At-Risk (PYAR)Figure 1
AIDS-related PCNSL in Norway: new cases, incidence rates and Person-Years-At-Risk (PYAR). New cases diag-
nosed with AIDS-related PCNSL (a), annual incidence rate per 100 Person-Years-At-Risk (PYAR) (b) and PYAR (c) the three 
5-year periods: 1989–1993, 1994–1998 and 1999–2003, in Norway.
BMC Cancer 2008, 8:225 http://www.biomedcentral.com/1471-2407/8/225and 1999–2003, respectively; Fischer's Exact Test: p =
0.96).
Patient characteristics are listed in Table 1. Twenty-six
(90%) of the 29 patients were male. Mean age at diagnosis
of PCNSL was 39.0 years. The histologic diagnosis was dif-
fuse large B-cell lymphoma in all patients. Only 2 patients
had this diagnosis established while alive (in 2000 and
2003, based on open biopsy). Immunohistochemistry
was positive with CD20 and Ki67 and negative with CD3
in 29/29 (100%). Epstein-Barr virus hybridization was
positive in 25/25 (100%). Polymerase chain reaction





Supposed mode of transmission
Homosexual 17 (59)
Heterosexual 8 (28)
Drug addict 2 (7)
Unknown 2 (7)
Duration of HIV-infection prior to AIDS: mean; median (range) months 38.6; 32.0 (0–118)
AIDS-defining disease
Pneumocystis jirovecii pneumonia 16 (55)
PCNSL 6 (21)
Tuberculosis 1 (3)
Cytomegalovirus infection 1 (3)
Kaposis sarcoma 2 (7)
Candida esophagitis 3 (10)
Duration of AIDS prior to PCNSL: mean; median (range) months 19.1; 15.0 (0–81)
Age at diagnosis of PCNSL: mean; median (range) years 39.0; 37.9 (24–54)
Symptoms on admission
Focal neurological 11 (38)
Personality change 14 (48)
Cerebellar symptoms/vertigo 10 (35)
Headache 10 (35)
Visual disturbance 6 (21)
Epilepsy 8 (28)
Performance status on admission
WHO PS 0–1 8 (28)
WHO PS 2–4 21 (72)
CD4 lymphocyte count (cells/μL): mean; median (range) (n = 24)a 26.6; 10.0 (0–190)
Lesions on CT/MR according to imaging report
No focal lesion 4 (14)
Single 8 (28)
Multiple 17 (59)
Lesions on CT/MR at review (in 14 patients)
Mean; median (range) number of lesions per patient 2.6; 2.0 (0–7)
Supratentorial involvement 14 (100)
Lobes 11 (79)
Deep structures 8 (57)
Posterior fossa involvement 2 (14)
Mean; median (range) size (diameter in mm) of lesions (n = 37) 24.2; 23.0 (6–55)
Treatment received
Steroid medication 11 (38)
Radiotherapyb 2 (7)
HAART 4 (14)
Toxoplasma therapyc 20 (69)
PCNSL = primary central nervous system lymphoma; WHO PS = World Health Organization performance status; CT = computed tomography; 
MRI = magnetic resonance imaging; HAART = highly active antiretroviral therapy.
aCD4 lymphocyte count at time of first symptom attributable to PCNSL.
bWhole brain radiation was given to 2 patients diagnosed with PCNSL while alive (24 Gy in 8 fractions to one patient and 30 Gy in 10 fractions to 
one).
cOnly 2 patients had favourable clinical and radiological response.Page 4 of 8
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death demonstrated positive Epstein-Barr virus DNA in 3/
5 (60%) and negative Toxoplasma gondii DNA in 2/2
(100%).
Review of CT/MRI in 14 patients revealed no brain lesion
in 1 (7%), a single lesion in 2 (14%), and multiple (2–7)
lesions in 11 (79%) patients. In the patient with no
lesion, CT one week prior to death indicated hydrocepha-
lus. All together, 37 lesions (36 at CT and 9 at MRI) were
identified; involving the lobes in 11 patients (79%) and
the deep structures of the brain in 8 patients (57%) (Table
1). All lesions enhanced after intravenous contrast injec-
tion; 75% showed ring-enhancement both at CT (27/36)
and MRI (6/8) (Figure 2).
The two patients diagnosed while alive received whole
brain radiation; no patients received cancer chemother-
apy. HAART was given to 4/7 (57%) diagnosed after the
introduction of HAART in Norway (August 1996). In 3
patients HAART was started mean (median, range) 4.3
(3.0, 2–8) months prior to first symptom of PCNSL and
was continued after symptom debut. Only one of these
had a favourable clinical and haematological response,
with normalization of CD4 cell count; this response was
first achieved after PCNSL was diagnosed. In one patient
HAART was started after PCNSL was diagnosed and gave
no favourable response. Toxoplasma therapy was given to
20/29 (69%) patients; 2 responded with clinical improve-
ment and regress of imaging findings but both died rap-
idly after their symptoms relapsed 1 and 15 months after
initial toxoplasma therapy, respectively.
Median survival from first symptom attributable to
PCNSL was 2.3 (95% CI: 1.5–3.2) months. Only 21% (6/
29) and 7% (2/29) were alive at 6 months and 1 year,
respectively (Figure 3), but one patient has survived for
4.5 years. In this patient PCNSL was established by biopsy
3 months after debut of personality changes; he received
HAART and radiotherapy and was alive > 4 years after
completed radiotherapy. All deaths (n = 28) were caused
by AIDS and PCNSL. Autopsy revealed cerebral toxoplas-
mosis in addition to PCNSL in 1 patient (not responding
to toxoplasma therapy).
Discussion
Different from non AIDS-related PCSNL in Norway [18],
the incidence of AIDS-related PCNSL in Norway
decreased in 1989–2003. Previous single- and multicenter
studies [8-12] have also found decreasing incidence of
AIDS-related PCNSL in the era of HAART. However, to our
knowledge, this is the first national survey to confirm
these findings.
Our survey had both strengths and limitations. It was
based on case reporting to a national cancer registry and a
comprehensive search for non-reported cases in the
autopsy registry at the hospital treating most AIDS
patients in Norway. Furthermore, all cases were histologi-
cally verified. However, due to the small sample size and
the very few patients diagnosed and treated while alive, we
could not assess prognostic factors. Also, most radiologi-
cal images from 1989–1993 were unavailable. The imag-
ing results should still be quite representative for the years
1994–2003 since images were reviewed for 76% (13/17)
of the patients from this time period.
Our figures for incidence rate (1.7 per 100 person-years)
and lifetime risk (5.5%) of PCNSL among AIDS patients
are in the upper range of figures in other studies
[1,6,9,15,20]. Lower incidence rates were reported from
the US [9,15]: the absolute incidence rate of brain lym-
phoma per 1000 person-years among AIDS patients was
4.7 in 1981–1990 [15] and 8.4 and 1.1 in 1988–1995 and
1996–2000 [9], respectively. Although not truly compara-
ble with rates among AIDS patients, reported incidence
rates of PCNSL per 1000 person-years among HIV-
infected individuals in Europe were 0.3–5.3 in 1983–
2002 [11] and 0.4–8.3 in 1994–2000 [10].
Autopsy in all AIDS patients is needed to truly estimate
the incidence of AIDS-related PCNSL. In our study, 93%
(27/29) had the diagnosis of PCNSL first established by
autopsy. None of these patients had a biopsy performed
while alive, and 15% (4/27) of them had no focal brain
AIDS-related PCNSL in Norway: imaging findings at CT and MRIFigure 2
AIDS-related PCNSL in Norway: imaging findings at 
CT and MRI. Contrast enhanced CT in 3 patients demon-
strating lesions with ring-enhancement in the frontal lobes 
(a), cerebellum (b) and basal ganglia (c). MRI (d-f) in another 
patient with lesion in the basal ganglia at T1 (d-e) and T2 (f) 
weighted images.Page 5 of 8
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Furthermore, PCNSL was considered a likely differential
diagnosis prior to death in only 35% (8/23) of those with
focal brain lesions, whereas cerebral toxoplasmosis was
considered likely in 91% (21/23).
The short median survival from first symptom attributa-
ble to PCNSL (2.3 months) was similar to survival times
in other larger materials (1.0–2.8 months) [8,16,17].
However, lack of a prompt diagnosis of PCNSL may have
excluded patients with very poor performance status from
optimal treatment. Long time survival of more than 4.5
years was achieved in one patient treated with radiother-
apy and HAART. Similar cases have been reported by oth-
ers [7,21].
Good performance status, higher CD4 count, whole brain
irradiation and HAART have favourable impact on sur-
vival in AIDS-related PCNSL [1,8,22,23]. Early diagnosis,
to ensure optimal treatment before the performance sta-
tus has declined, is thus essential. In our study, all but 4 of
the 27 patients first diagnosed at autopsy had focal brain
lesion(s) on CT/MRI, which should raise the suspicion of
PCNSL. Furthermore, 17 of 19 patients with focal
lesion(s) who received toxoplasma therapy, showed no
clear response. None of these 17 patients underwent ster-
eotactic or open biopsy which may be partly explained by
the bad performance status (WHO 2–4) in most of them
(77%, 13/17).
Delayed diagnosis of PCNSL is a concern with empiric
toxoplasma therapy [1,22]. To reduce this delay, brain
biopsy is advised when there is clinical or radiological
deterioration during the first week of initial toxoplasma
therapy or lack of clinical improvement within 2 weeks
[1,24]. Also, PCNSL can be diagnosed without awaiting
toxoplasma therapy or biopsy, based on CSF Epstein-Barr
virus DNA and 201Tl single-photon emission computed
Survival curve for patients with AIDS-related PCNSL in NorwayFigure 3
Survival curve for patients with AIDS-related PCNSL in Norway. Kaplan-Meier survival curve with 95% confidence 
interval for patients with AIDS-related PCNSL (n = 29). Median survival from first symptom attributable to PCNSL was 2.3 
(95% CI: 1.5–3.2) months.Page 6 of 8
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rapid, accurate and minimally invasive diagnosis may be
achievable, although the accuracy of this diagnostic
approach is not fully clarified in the era of HAART [2].
The present MRI/CT findings are similar to those in toxo-
plasmosis [1,25]. MRI and CT can seldom differentiate
lymphoma from toxoplasmosis [1,20]. If available, diffu-
sion or perfusion MRI, magnetic resonance spectroscopy,
positron emission tomography and SPECT [1,25] might
help to select patients for biopsy versus empiric toxo-
plasma therapy. So might PCR examination of the CSF to
detect Ebstein-Barr virus DNA or Toxoplasma gondii DNA
[1,2], but none of these tests are completely specific.
Biopsy is often needed, but should be weighted against its
relatively high procedural risk in AIDS patients [1]. Fur-
ther research on the combination of less invasive diagnos-
tic procedures is required to reduce the need for biopsy.
Conclusion
This national survey showed decreasing incidence rate of
AIDS-related PCNSL in Norway during 1989–2003. AIDS
patients in Norway had a 5.5% lifetime risk of PCNSL,
emphasizing the importance of PCNSL as organ-specific
manifestation of AIDS. Despite dismal survival in most
patients (median 2.3 months), the possibility of long
term survival should prompt more aggressive diagnostics
in suspected PCNSL.
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